Fibrolamellar Global Summit Determines Research Funding As #GivingTuesday Top Priority
Industry: Healthcare
Help fund rare cancer research. FCF's #GivingTuesday initiative https://fibrofoundation.org/donate/
Greenwich, CT (PRUnderground) November 22nd, 2017
#GivingTuesday, a global day of giving, arrives just in time to help rare cancers, a desperately underfunded nonprofit category, that has real potential to save lives.
At a global summit held earlier this month by the Fibrolamellar Cancer Foundation (FCF), an organization supporting research for a rare form of liver cancer, over a dozen prestigious research institutions, including the National Cancer Institute (NCI), along with some of the world’s top GI cancer MDs and PhDs from academia, industry and government, collaborated and exchanged information. While many potential breakthroughs were discussed, the overwhelming theme was that significant improvements for treatments and curative therapies could be discovered given additional resources for research.
As a part of this effort, FCF today announced its participation in #GivingTuesday (November 28, 2017), which is held annually on the Tuesday after Thanksgiving (in the U.S.) as a kick off to the holiday giving season.
John Hopper, President of the Greenwich-CT based FCF and Co-Chair of the GI Cancers Alliance (GICA), said, “Rare cancers tend to get overlooked. We are especially fortunate to be a part of the #GivingTuesday movement because this is a time when people from all walks of life can truly make a major difference. Donating to a rare disease like Fibrolamellar, which has a very low survival rate and few specific treatments, can make a major difference for the children and young adults facing this cancer. We encourage everyone to think of FCF on #GivingTuesday.”
Those who are interested in joining FCF’s #GivingTuesday initiative can visit https://fibrofoundation.org/donate/
About Fibrolamellar Cancer Foundation
FCF, a public 501c3 nonprofit organization based in Greenwich, CT, was founded in 2009 by 27-year-old Tucker Davis, who lost his life to Fibrolamellar on Rare Disease Day in 2010, after an 18-month fight. FCF has funded nearly $10 million in research across more than 24 major institutions in the U.S. and internationally. 100% of all donations go towards research. All FCF’s overhead and administrative costs are paid by the Charles A. and Marna Davis Foundation and Stone Point Capital. For more information, visit www.fibrofoundation.org
